Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma

Cancer

Volumn 104, Issue 7, 2005, Pages 1372-1380

  Copeland, Laurel A ^a   Elshaikh, Mohamed A ^b,c   Jackson, James ^b   Penner, Louis A ^b,d   Underwood III, Willie ^b,c,e  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

External beam radiation therapy; Permanent prostate brachytherapy; Prostate carcinoma; Radical prostatectomy

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; GEOGRAPHY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RACE DIFFERENCE;

ADULT; AGE FACTORS; AGED; ATTITUDE TO HEALTH; BRACHYTHERAPY; CONFIDENCE INTERVALS; CONTINENTAL POPULATION GROUPS; DISEASE-FREE SURVIVAL; HUMANS; LOGISTIC MODELS; MALE; MARITAL STATUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEER PROGRAM; STRESS, PSYCHOLOGICAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 25144501953     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21341     Document Type: Article

References (25)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171:1504-1507.
3. Bubolz T, Wasson JH, Lu-Yao G, Barry MJ. Treatments for prostate cancer in older men: 1984-1997. Urology. 2001;58:977-982.
4. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13:93-100.
5. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1679-1684.
6. Lai S, Lai H, Lamm S, Obek C, Krongrad A, Roos B. Radiation therapy in non-surgically-treated nonmetastatic prostate cancer: geographic and demographic variation. Urology. 2001;57:510-517.
7. Underwood W, Jackson J, Wei J, et al. Racial/ethnic treatment trends in localized/regional prostate cancer from 1992 thru 1999. Cancer. 2005;103:538-545.
8. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland [review]. J Urol. 2003;169:1643-1652.
9. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer [review]. Int J Radiat Oncol Biol Phys. 1999;44:789-799.
10. Ghaly M, Wallner K, Merrick G1 et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys. 2003;55:1288-1293.
11. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
12. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522.
13. Potters L. Permanent prostate brachytherapy in men with clinically localised prostate cancer. Clin Oncol. 2003;15:301-315.
14. Mettlin CJ, Murphy GP, McDonald CJ, Menck HR. The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer. 1999;86:1877-1882.
15. Ragde H, Grado GL, Nadir B, Elgamal AA. Modern prostate brachytherapy. CA Cancer J Clin. 2000;50:380-393.
16. Surveillance, Epidemiology, and End Results (SEER) program populations (1969-2000). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2003. Available from URL: http:// www.seer.cancer.gov/popdata [accessed February 5, 2004].
17. Tewari A, Menon M. Vattikuti Institute prostatectomy: surgical technique and current results. Curr Urol Rep. 2003;4:119-123.
18. Hemal AK, Menon M. Robotics in urology [review]. Curr Opin Urol. 2004;14:89-93.
19. Sarle R, Tewari A, Shrivastava A, Peabody J, Menon M. Surgical robotics and laparoscopic training drills. J Endourol. 2004;18:63-66; discussion 66-67.
20. Abreu SC, Sharp DS, Ramani AP, et al. Thoracic complications during urological laparoscopy. J Urol. 2004;171:1451-1455.
21. Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996;124:577-584.
22. Fowler FJ Jr., Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526-532.
23. Mazur DJ, Hickman DH. Patient preferences: survival vs quality-of-life considerations. J Gen Intern Med. 1993;8:374-377.
24. Volk RJ, Cantor SB, Cass AR, Spann SJ, Weller SC, Krahn MD. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med. 2004;19:339-348.
25. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098-1104.